What is the mechanism of action of this treatment?

Common treatments for neurological diseases include pharmacological and non-pharmacological interventions. Pharmacological treatments, such as cholinesterase inhibitors and memantine, work by modulating neurotransmitter levels to improve cognitive and motor functions. Non-pharmacological interventions, like computerized cognitive tests, aim to enhance brain function through structured cognitive exercises. These treatments are essential for neurological disease patients as they can slow disease progression, improve quality of life, and help maintain cognitive and motor functions.

What side effects are associated with this type of intervention?

Common treatments for neurological diseases, such as cholinesterase inhibitors (e.g., donepezil, rivastigmine) and memantine, often used in cognitive impairment and dementia, have known side effects. Cholinesterase inhibitors can cause nausea, vomiting, diarrhea, muscle cramps, and increased tremors. Memantine may lead to dizziness, headache, confusion, and, in some cases, hallucinations or worsened neuropsychiatric symptoms. These side effects are important to monitor during treatment, especially when using digital tools for cognitive assessment.

What prior FDA approvals exist?

The FDA has approved several treatments for neurological diseases, particularly those targeting cognitive impairments and dementia. Notable drugs include cholinesterase inhibitors like donepezil, which are used to manage symptoms of Alzheimer's disease and other dementias. Additionally, memantine has been approved for moderate to severe Alzheimer's disease. While the context does not provide specific examples of FDA-approved computerized cognitive tests, there is ongoing research into digital tools for assessing brain function, such as the Montreal Cognitive Assessment (MoCA), which is available online and used to track cognitive changes over time.

What other types of research exist?

Promising, novel alternatives to computerized cognitive tests for neurological disease patients include the Alabama Brief Cognitive Screener (ABCs) for cognitive screening, and transcranial direct current stimulation (tDCS) for enhancing cognitive functions such as naming accuracy in aphasia patients. These methods offer new approaches to cognitive assessment and treatment, potentially improving patient outcomes in 2024.

← Back to Search

N/A

Computerized Cognitive Tests for Neurological Disease

N/A

Recruiting

Led By Alexander Chervinsky, PhD

Research Sponsored by NYU Langone Health

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Participants will be male or female and between the ages of 21 and 65 years old.

Be older than 18 years old

Must not have

Participants without adequate perceptual and motor capacities preventing them from participation in the testing.

Participants with severe dysfunction at the level of dementia that can interfere with informed consent.

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Summary

This trial is testing three new computer-based tasks to measure brain and thinking skills. It involves both healthy people and those with neurological problems. The study aims to see if these new tasks are as good as traditional paper tests by comparing results from both methods.

Who is the study for?

This trial is for men and women aged 21-65, both healthy individuals and those with significant brain findings on neuroimaging. Participants must have good perception and motor skills to do the tests but can't join if they have severe dementia or lack the necessary perceptual/motor abilities.

What is being tested?

The study is testing three new computer-based cognitive function tests against traditional paper-and-pencil methods. It aims to see if these digital tasks are more effective by comparing results from healthy controls and patients with neurological impairments.

What are the potential side effects?

Since this trial involves non-invasive neuropsychological testing, there are no direct physical side effects expected from participating in this study.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 21 and 65 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I am physically and mentally able to participate in tests.

Select...

I do not have severe dementia that affects my understanding.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

2Treatment groups

Active Control

Group I: Non-CNI participantsActive Control10 Interventions

Identified from the department of Rehabilitation, Psychiatry, and Medicine and referred to the research staff via in-person communication, email or staff message

Group II: Cerebral neurological illness (CNI) participantsActive Control10 Interventions

Identified from the department of Rehabilitation, Psychiatry, and Medicine and referred to the research staff via in-person communication, email or staff message

0 / 3Eligibility criteria met

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

Common treatments for neurological diseases include pharmacological and non-pharmacological interventions. Pharmacological treatments, such as cholinesterase inhibitors and memantine, work by modulating neurotransmitter levels to improve cognitive and motor functions. Non-pharmacological interventions, like computerized cognitive tests, aim to enhance brain function through structured cognitive exercises. These treatments are essential for neurological disease patients as they can slow disease progression, improve quality of life, and help maintain cognitive and motor functions.

Methodological recommendations for cognition trials in bipolar disorder by the International Society for Bipolar Disorders Targeting Cognition Task Force.

Find a Location

Who is running the clinical trial?

NYU Langone HealthLead Sponsor

1,397 Previous Clinical Trials

861,642 Total Patients Enrolled

Alexander Chervinsky, PhDPrincipal InvestigatorNYU Langone Health

Media Library

Computer-based Neuropsychological Tool (N/A) Clinical Trial Eligibility Overview. Trial Name: NCT03502603 — N/A

Neurological Disease Research Study Groups: Non-CNI participants, Cerebral neurological illness (CNI) participants

Neurological Disease Clinical Trial 2023: Computer-based Neuropsychological Tool Highlights & Side Effects. Trial Name: NCT03502603 — N/A

Computer-based Neuropsychological Tool (N/A) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03502603 — N/A

~6 spots leftby Dec 2024

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.